Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 10Urinary Bladder Neoplasms 3Stomach Neoplasms 3Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Uveal Melanoma 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Rectal Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Carcinoma, Basal Cell 2Advanced Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Spinocerebellar Degenerations 1Sarcoma 1

Interventions

Nivolumab 5pembrolizumab 3avelumab 3Neoadjuvant Therapy 3toripalimab 2durvalumab 2atezolizumab 2Celecoxib 2spartalizumab 1relatlimab 1fludarabine phosphate 1fludarabine 1dostarlimab 1danvatirsen 1XELOX 1Surgical Procedures, Operative 1Oxaliplatin 1Leucovorin 1Ipilimumab 1Induction Chemotherapy 1Immunotherapy 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1IMM-101 1Fluorouracil 1Docetaxel 1Disulfides 1DEAE-Dextran 1Cyclophosphamide 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Turcot syndrome × relatlimab × Clear all
NCT03607890 2026-03-16

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
38 enrolled

Turcot syndrome, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡